Physician profile
Inder Lal
NPI 1124227889
$41,950.37
in general payments reported to CMS, 2019-2025
17 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $113 · 2021: $120 · 2022: $5,795 · 2023: $3,336 · 2024: $17K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,970 · Travel and Lodging: $4,511 · Honoraria: $2,300 · Food and Beverage: $979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,865.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,970.00 |
| Travel and Lodging | $4,511.40 |
| Honoraria | $2,300.00 |
| Food and Beverage | $978.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $22,826.08 | 2022-2025 | Imfinzi, Enhertu, Lynparza |
| Exelixis INC. | $5,390.34 | 2023-2025 | Cabometyx |
| Pfizer INC. | $5,194.84 | 2024-2025 | |
| Springworks Therapeutics, INC. | $2,070.00 | 2024 | Ogsiveo |
| Janssen Biotech, INC. | $1,470.00 | 2024 | Carvykti |
| Daiichi Sankyo INC. | $1,400.00 | 2022-2025 | Vanflyta |
| Beigene USA, INC. | $1,200.00 | 2022-2024 | Brukinsa |
| Incyte Corporation | $956.83 | 2019-2025 | |
| Geron Corporation | $735.78 | 2025 | Imetelstat |
| Sobi, INC | $200.00 | 2024 | |
| Amgen INC. | $112.53 | 2020 | |
| Alexion Pharmaceuticals, INC. | $99.00 | 2019 | |
| Epizyme, INC. | $82.95 | 2021 | |
| Genentech USA, INC. | $81.22 | 2019 | |
| Rigel Pharmaceuticals, INC. | $73.43 | 2023 | Tavalisse, Rezlidhia |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $45.45 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inder Lal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.